Výsledky vyhledávání - "Christina H. Arce"

Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A

Autor: Eva M Ciruelos, Florence Lerebours, Hope S Rugo, Manuel Ruiz-Borrego, Pamela Drullinsky, Aleix Prat, Thomas Bachelot, Patrick Neven, Yeon Hee Park, Nicholas Turner, Dejan Juric, Ennan Gu, Christina H Arce, Murat Akdere, Stephen Chia

Publikováno v: Cancer Research. 82:P1-18

Introduction: In HR+, HER2- ABC, activating PIK3CA mutations occur in ~40% of tumors and confer worse prognosis, including endocrine therapy (ET) resistance. BYLieve (NCT03056755) is an ongoing Phase II, open-label, 3-cohort noncomparative study, eva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1e3e43f6413409edfa91d6789759b96b
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-03

Zobrazit plný text záznamu

Abstract P5-13-03: Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study

Autor: Dejan Juric, Nicholas Turner, Aleix Prat, Stephen Chia, Eva M Ciruelos, Manuel Ruiz-Borrego, Pamela Drullinsky, Florence Lerebours, Thomas Bachelot, O. Alejandro Balbin, Mukta Joshi, Estelle Roux, Christina H Arce, Murat Akdere, Hope S Rugo

Publikováno v: Cancer Research. 82:P5-13

Introduction: Alpelisib (ALP, a PI3Kα inhibitor and degrader) + ET has demonstrated efficacy in patients (pts) with HR+, HER2-, PIK3CA-mutated ABC progressing on/after CDK4/6i + ET in the ongoing Phase II BYLieve study (NCT03056755). The primary end

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::04727c17d76a87c9e9e71fa8c210eb80
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-03

Zobrazit plný text záznamu

Abstract PD13-05: Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses

Autor: Hope S Rugo, Patrick Neven, Isabel Saffie, Yeon Hee Park, Michelino De Laurentiis, Florence Lerebours, Eva Maria Ciruelos, Nicholas Turner, Dejan Juric, Ennan Gu, Christina H Arce, Mukta Joshi, Estelle Roux, Murat Akdere, Stephen Chia

Publikováno v: Cancer Research. 82:PD13-05

Introduction: Alpelisib (ALP), an inhibitor and degrader of phosphatidylinositol-3-kinase α (PI3Kα), + fulvestrant (FUL) demonstrated efficacy in PIK3CA-mutated, HR+, HER2- ABC in the phase 3 SOLAR-1 trial, which included only 20 patients (pts) wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::47d5972c1288bd6132bd2e2cde286c88
https://doi.org/10.1158/1538-7445.sabcs21-pd13-05

Zobrazit plný text záznamu

Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study

Autor: Dejan Juric, Hope S. Rugo, Stephen K.L. Chia, Florence Lerebours, Manuel Ruiz-Borrego, Pamela Drullinsky, Eva M. Ciruelos, Patrick Neven, Yeon Hee Park, Christina H. Arce, Ennan Gu, Mukta Joshi, Estelle Roux, Murat Akdere, Nicholas C. Turner

Publikováno v: Journal of Clinical Oncology. 40:1018-1018

1018 Background: ALP (PI3K-α selective inhibitor and degrader) + fulvestrant (FUL) is approved for pts with HR+, HER2– ABC and a tumor mutation in PIK3CA (̃ 40% of these pts). Primary analyses from the Phase 2 BYLieve study demonstrated efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7669b2bb2b1ac09cf64988179de5b5a3
https://doi.org/10.1200/jco.2022.40.16_suppl.1018

Zobrazit plný text záznamu

Abstract PD15-01: Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial

Autor: Nick Turner, Hope S Rugo, Eva M Ciruelos, Manuel Ruiz-Borrego, Pamela Drullinsky, Florence Lerebours, Aleix Prat, Thomas Bachelot, Stephen Chia, Alejandro Balbin, Mukta Joshi, Estelle Roux, Christina H Arce, Murat Akdere, Dejan Juric

Publikováno v: Cancer Research. 82:PD15-01

Introduction: Endocrine-based therapy is the standard of care for patients (pts) with HR+ ABC. Acquired ESR1 mutations (mut) have been reported in up to 56% of pts with HR+ ABC progressing after prior treatment with ET, and aromatase inhibitors (AIs)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75c8e461b48d42b042a51c12f3eba37d
https://doi.org/10.1158/1538-7445.sabcs21-pd15-01

Zobrazit plný text záznamu

Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations

Autor: Laurence J. Hirsch, Christina H. Arce, Michael Gibney, Karen Byron

Publikováno v: Current medical research and opinion. 26(6)

During subcutaneous insulin therapy, inadvertent intramuscular (IM) injections may increase pain and/or adversely affect glucose control. The most appropriate needle length for patients depends on skin thickness (ST) and the distance to muscle fascia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcd75cd7ade49e20f828f10efc7df8ec
https://pubmed.ncbi.nlm.nih.gov/20429833

Zobrazit plný text záznamu

Akademický článek

Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations.

Autor: Michael A. Gibney, Christina H. Arce, Karen J. Byron, Laurence J. Hirsch

Publikováno v: Current Medical Research & Opinion; Jan2010, Vol. 26 Issue 6, p1519-1530, 12p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání